Download your copy of the report:
The market interest surrounding anti-tumour CAR-T therapies was one of the defining themes of 2014 and investor enthusiasm for the area is unlikely to abate in 2015. But there may be hidden dangers for those seeking to make big returns, according to a report published by EP Vantage, based on market intelligence from EvaluatePharma.
CAR-T therapies aim to activate the body’s immune system to fight tumour cells. As CAR-T therapies progress down the development pathway, the EP Vantage CAR-T Therapy Landscape in 2015 report explores some of the key issues being raised, including:
The fact that very few patients have been treated through CAR-T clinical trials and adverse events have led to patient deaths
The fear that companies like Juno Therapeutics and Kite Pharma could now face massive risks to their valuations in what is an increasingly crowded space, one that could be characterised by extensive litigation over intellectual property
The reality that deals will continue as companies scramble to jump on the CAR-T bandwagon, pushing asset prices sky-high.
This comprehensive report covers:
The most promising candidates in development
The most clinically advanced products
A detailed look at the largely ignored risks of CAR-T therapy
Strategies to increase safety
Intellectual property issues
Beyond CAR-T - the next generation of products
Smaller companies to watch
To download this report, please confirm your details on the form opposite.